Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


MedImmune lowers FluMist guidance

Executive Summary

MedImmune reduces fourth quarter and full-year revenue guidance based on low demandfor its intranasal flu vaccine FluMist. Vaccine now expected to bring in $55 mil.-$85 mil. for 2003 instead of $120-$140 mil; total revenue expectations for the year reduced to $1.04 bil.-$1.1 bil. from $1.1 bil-$1.15 bil. MedImmune expects to record $10 mil. in FluMist "manufacturing supply goal payments and contractual reimbursements" in the fourth quarter and "manufacturing transfer payments and royalties" in the range of $7 mil-$37 mil. Wyeth has provisions in place for accepting FluMist returns (1"The Pink Sheet" Nov. 17, 2003, p. 35)...

You may also be interested in...

Wyeth Offering FluMist Coupons; Prevnar Supply Issue “Resolved,” FDA Says

Wyeth and MedImmune plan to increase couponing for FluMist in the coming months

European SEAC Opinion Unchanged: Microplastics Must Be Out Of All Cosmetics Within Six Years

The final opinion of ECHA’s Socio-Economic Analysis Committee, published on 1 March, is largely unchanged from its July 2020 draft opinion with regard to microplastic in cosmetic products. That means industry may have to convince EU member state authorities that the restriction proposal has a serious proportionality problem.

QUOTED. 2 March 2021. Michael Coyle.

Representatives from cardiac monitoring device manufacturers and professional societies are working together to persuade Medicare carrier Novitas to reconsider its payment rates for extended cardiac monitoring. See what Michael Coyle, iRhythm’s CEO, said about it here.




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts